Acceleron Pharma Inc. | Mutual Funds
Mutual Funds that own Acceleron Pharma Inc.
Fidelity Select Biotechnology Portfolio
2,058,599
4.47%
901,116
1.21%
07/31/2018
T Rowe Price Health Sciences Fund
1,331,728
2.9%
329,593
0.56%
06/30/2018
Vanguard Total Stock Market Index Fund
963,545
2.1%
0
0.01%
07/31/2018
T Rowe Price New Horizons Fund
892,035
1.94%
180,869
0.2%
06/30/2018
SPDR S&P Biotech ETF
848,404
1.84%
2,184
0.78%
09/06/2018
iShares Russell 2000 ETF
813,784
1.77%
-435
0.09%
09/06/2018
Fidelity Contrafund
734,033
1.6%
734,033
0.03%
07/31/2018
Eagle Small Cap Growth Fund
657,640
1.43%
-285,204
0.62%
06/29/2018
BlackRock Health Sciences Opportunities Portfolio
651,100
1.42%
0
0.49%
06/29/2018
Fidelity Select Health Care Portfolio
550,000
1.2%
150,000
0.39%
07/31/2018
| Address |
128 Sidney Street
Cambridge Massachusetts 02139
United States
|
|
Employees
|
- |
| Website |
http://www.acceleronpharma.com |
| Updated |
07/08/2019 |
| Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. |
